FHTX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Foghorn Therapeutics Inc (FHTX) is not a strong buy for a beginner, long-term investor with $50,000-$100,000 available for investment. The stock lacks immediate positive catalysts, has weak financial performance, and no significant trading signals. While analysts have a favorable long-term view, the investment horizon is tied to clinical trial data expected in 2026, making it unsuitable for an impatient investor.
The technical indicators show mixed signals. The MACD is negative and expanding downward, indicating bearish momentum. RSI is neutral at 47.751, showing no clear trend. Moving averages are bullish (SMA_5 > SMA_20 > SMA_200), but the stock is trading near its pivot level of 5.625, with limited upside potential in the short term.
The company's gross margin remains strong at 100%.
No recent news or significant insider/hedge fund activity. Financial performance is weak, with a YoY drop in net income (-17.12%) and EPS (-19.35%). The stock has a 50% chance of declining in the next day (-1.68%), week (-3.55%), and month (-6.88%).
In Q3 2025, revenue increased by 4.42% YoY to $8.15M, but net income dropped by 17.12% YoY to -$15.85M. EPS declined by 19.35% YoY to -0.25. Gross margin remains strong at 100%, but overall financials indicate weak profitability.
Jefferies lowered the price target to $12 from $14 while maintaining a Buy rating, citing potential for significant price movement based on clinical trial data in 2026. BTIG initiated coverage with a Buy rating and an $11 price target, viewing the stock as undervalued ahead of Phase 1 data for FHD-909.
